Jordi Rio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9358280/publications.pdf

Version: 2024-02-01

121 papers	6,318 citations	66343 42 h-index	74163 75 g-index
132 all docs	132 docs citations	132 times ranked	5645 citing authors

#	Article	IF	Citations
1	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. European Journal of Neurology, 2022, 29, 1075-1081.	3.3	16
2	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsingâ€“remitting multiple sclerosis patients. Journal of Neurology, 2022, 269, 452-459.	3.6	10
3	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 950-957.	3.0	7
4	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. Journal of Neurology, 2022, 269, 1764-1772.	3.6	5
5	Herpes simplex encephalitis in the context of immune checkpoint inhibitors: a complex interplay. Acta Neurologica Belgica, 2022, 122, 823-825.	1.1	3
6	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, e1143.	6.0	17
7	Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice. Neuroscience Informatics, 2022, 2, 100071.	4.5	1
8	Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. Multiple Sclerosis and Related Disorders, 2022, 63, 103805.	2.0	2
9	Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 732-740.	1.9	8
10	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. Multiple Sclerosis Journal, 2022, 28, 1138-1145.	3.0	11
11	Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)â€”a systematic review protocol. Systematic Reviews, 2022, 11, .	5.3	0
12	Adding brain volume measures into response criteria in multiple sclerosis: the RÃo-4 score. Neuroradiology, 2021, 63, 1031-1041.	2.2	2
13	COVIDâ€19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. European Journal of Neurology, 2021, 28, 3384-3395.	3.3	111
14	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. Multiple Sclerosis Journal, 2021, 27, 913-921.	3.0	20
15	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	12
16	Scoring the 10â€year risk of ambulatory disability in multiple sclerosis: the RoAD score. European Journal of Neurology, 2021, 28, 2533-2542.	3.3	16
17	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology, 2021, 97, e1641-e1652.	1.1	35
18	Optic Nerve Topography in Multiple Sclerosis Diagnosis. Neurology, 2021, 96, e482-e490.	1.1	32

#	Article	IF	Citations
19	A pharmacogenetic study implicates NINJ2 in the response to Interferon-Î² in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1074-1082.	3.0	5
20	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Multiple Sclerosis Journal, 2020, 26, 1658-1669.	3.0	41
21	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nature Reviews Neurology, 2020, 16, 171-182.	10.1	150
22	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology, 2019, 92, e1507-e1516.	1.1	49
23	Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis. Neurology, 2019, 92, 296-298.	1.1	15
24	Unraveling treatment response in multiple sclerosis. Neurology, 2019, 92, 180-192.	1.1	88
25	Clinical commentary on â€œTwo cases of anaphylactic shock by methylprednisolone in neuromyelitis opticaâ€• Multiple Sclerosis Journal, 2018, 24, 1516-1517.	3.0	0
26	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain, 2018, 141, 1075-1084.	7.6	98
27	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	7.6	115
28	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Multiple Sclerosis Journal, 2018, 24, 301-312.	3.0	79
29	Disability progression markers over 6â€“12â€‰years in interferon-Î²-treated multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 322-330.	3.0	60
30	Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab. Multiple Sclerosis Journal, 2018, 24, 358-360.	3.0	17
31	Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. Journal of Neurology, 2018, 265, 24-31.	3.6	11
32	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 1507-1510.	3.0	11
33	Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. Journal of Neuroinflammation, 2018, 15, 296.	7.2	7
34	Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. Journal of Neuroimmunology, 2017, 303, 62-65.	2.3	16
35	MR Imaging in Monitoring and Predicting Treatment Response in Multiple Sclerosis. Neuroimaging Clinics of North America, 2017, 27, 277-287.	1.0	20
36	Lesion topographies in multiple sclerosis diagnosis. Neurology, 2017, 89, 2351-2356.	1.1	27

#	Article	IF	Citations
37	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Multiple Sclerosis Journal, 2017, 23, 556-566.	3.0	21
38	Neurofilament light chain level is a weak risk factor for the development of MS. Neurology, 2016, 87, 1076-1084.	1.1	85
39	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. Neurology, 2016, 87, 1368-1374.	1.1	42
40	Assessing response to interferon-Î² in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.1	98
41	Brain Volume Loss During the First Year of Interferonâ€Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. Journal of Neuroimaging, 2016, 26, 532-538.	2.0	21
42	Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis. Journal of the Neurological Sciences, 2016, 361, 158-167.	0.6	20
43	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. Human Molecular Genetics, 2016, 25, 308-316.	2.9	31
44	A 10-year follow-up of the European multicenter trial of interferon Î²-1b in secondary-progressive multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 533-543.	3.0	24
45	Pharmacogenomic study in patients with multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e154.	6.0	19
46	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. Multiple Sclerosis Journal, 2015, 21, 1802-1810.	3.0	10
47	Predictive value of early brain atrophy on response in patients treated with interferon Î². Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e132.	6.0	28
48	NLRP3 inflammasome is associated with the response to IFN-Î² in patients with multiple sclerosis. Brain, 2015, 138, 644-652.	7.6	93
49	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain, 2015, 138, 1863-1874.	7.6	403
50	Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis: No. Multiple Sclerosis Journal, 2015, 21, 132-133.	3.0	7
51	Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta. Journal of Neuroimmunology, 2015, 288, 98-101.	2.3	12
52	Significant clinical worsening after natalizumab withdrawal: Predictive factors. Multiple Sclerosis Journal, 2015, 21, 780-785.	3.0	43
53	Brain atrophy in natalizumab-treated patients: A 3-year follow-up. Multiple Sclerosis Journal, 2015, 21, 749-756.	3.0	51
54	Evaluating the response to glatiramer acetate in relapsingâ€“remitting multiple sclerosis (RRMS) patients. Multiple Sclerosis Journal, 2014, 20, 1602-1608.	3.0	36

#	Article	IF	Citations
55	Activation-induced cell death in T lymphocytes from multiple sclerosis patients. Journal of Neuroimmunology, 2014, 272, 51-55.	2.3	8
56	HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-Î² therapy in multiple sclerosis. Journal of Medical Genetics, 2014, 51, 395-400.	3.2	19
57	Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients. Autoimmunity, 2014, 47, 127-133.	2.6	17
58	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2013, 19, 742-748.	3.0	35
59	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Multiple Sclerosis Journal, 2013, 19, 1175-1181.	3.0	93
60	Treatment with interferon-beta does not induce anti-nuclear and anti-neuronal serum autoantibodies in multiple sclerosis patients. Journal of Neuroimmunology, 2013, 255, 102-104.	2.3	1
61	Roles of the ubiquitin peptidase <scp>USP</scp>18 in multiple sclerosis and the response to interferonâ€Î² treatment. European Journal of Neurology, 2013, 20, 1390-1397.	3.3	32
62	Cellular immune responses in multiple sclerosis patients treated with interferon-beta. Clinical and Experimental Immunology, 2013, 171, 243-246.	2.6	5
63	Clinical impact of early brain atrophy in clinically isolated syndromes. Multiple Sclerosis Journal, 2013, 19, 1878-1886.	3.0	85
64	Scoring treatment response in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 605-612.	3.0	227
65	Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta. PLoS ONE, 2013, 8, e60994.	2.5	27
66	Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment. PLoS ONE, 2013, 8, e82796.	2.5	23
67	EBV-specific immune responses in patients with multiple sclerosis responding to IFNÎ² therapy. Multiple Sclerosis Journal, 2012, 18, 605-609.	3.0	20
68	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. Multiple Sclerosis Journal, 2012, 18, 1193-1196.	3.0	19
69	Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. European Journal of Neurology, 2012, 19, 899-904.	3.3	55
70	Multiple sclerosis: current treatment algorithms. Current Opinion in Neurology, 2011, 24, 230-237.	3.6	65
71	IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. Journal of Neuroimmunology, 2011, 239, 101-104.	2.3	18
72	Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clinical Immunology, 2011, 141, 348-356.	3.2	72

#	Article	IF	Citations
73	Implication of the tollâ€like receptor 4 pathway in the response to interferonâ€Î²2 in multiple sclerosis. Annals of Neurology, 2011, 70, 634-645.	5.3	35
74	Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis. Archives of Neurology, 2011, 68, 1421.	4.5	44
75	Search for Specific Biomarkers of IFNÎ²2 Bioactivity in Patients with Multiple Sclerosis. PLoS ONE, 2011, 6, e23634.	2.5	45
76	Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. Journal of Neurology, 2010, 257, 742-746.	3.6	19
77	Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?. Multiple Sclerosis Journal, 2010, 16, 55-61.	3.0	54
78	Measures in the first year of therapy predict the response to interferon Î²2 in MS. Multiple Sclerosis Journal, 2009, 15, 848-853.	3.0	215
79	Predicting responders to therapies for multiple sclerosis. Nature Reviews Neurology, 2009, 5, 553-560.	10.1	114
80	A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1195-1205.	3.0	95
81	A type I interferon signature in monocytes is associated with poor response to interferon-Î²2 in multiple sclerosis. Brain, 2009, 132, 3353-3365.	7.6	186
82	Genome-wide Scan of 500Â000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis. Archives of Neurology, 2009, 66, 972-8.	4.5	104
83	HLA class I and II alleles and response to treatment with interferon-beta in relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 2009, 210, 116-119.	2.3	33
84	Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clinical Immunology, 2009, 130, 145-150.	3.2	41
85	Plasma chitotriosidase activity in multiple sclerosis. Clinical Immunology, 2009, 131, 216-222.	3.2	27
86	Plasma levels of 15dâ€PGJ₂ are not altered in multiple sclerosis. European Journal of Neurology, 2009, 16, 1197-1201.	3.3	7
87	The basal ganglia: a substrate for fatigue in multiple sclerosis. Neuroradiology, 2008, 50, 17-23.	2.2	91
88	Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. Journal of Neurology, 2008, 255, 1136-1141.	3.6	23
89	Relationship between MRI lesion activity and response to IFN-Î²2 in relapsingâ€“remitting multiple sclerosis patients. Multiple Sclerosis Journal, 2008, 14, 479-484.	3.0	104
90	Very early scans for demonstrating dissemination in time in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 631-635.	3.0	17

#	Article	IF	Citations
91	Identification of a Novel Risk Locus for Multiple Sclerosis at 13q31.3 by a Pooled Genome-Wide Scan of 500,000 Single Nucleotide Polymorphisms. PLoS ONE, 2008, 3, e3490.	2.5	99
92	Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort. Multiple Sclerosis Journal, 2007, 13, 731-736.	3.0	6
93	Interferon beta in secondary progressive multiple sclerosis. Journal of Neurology, 2007, 254, 849-853.	3.6	4
94	Interferons and cognition. Journal of the Neurological Sciences, 2006, 245, 137-140.	0.6	18
95	Reply to D. S. Goodin. Journal of Neurology, 2006, 253, 949-949.	3.6	0
96	Fatigue in multiple sclerosis persists over time. Journal of Neurology, 2006, 253, 1466-1470.	3.6	80
97	Defining the response to interferonâ€Î² in relapsingâ€remitting multiple sclerosis patients. Annals of Neurology, 2006, 59, 344-352.	5.3	295
98	Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Multiple Sclerosis Journal, 2006, 12, 487-494.	3.0	67
99	Plasma osteopontin levels in multiple sclerosis. Journal of Neuroimmunology, 2005, 158, 231-239.	2.3	171
100	Is optic neuritis more benign than other first attacks in multiple sclerosis?. Annals of Neurology, 2005, 57, 210-215.	5.3	108
101	Interferon beta in relapsingâ€“remitting multiple sclerosis. Journal of Neurology, 2005, 252, 795-800.	3.6	59
102	Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?. Multiple Sclerosis Journal, 2005, 11, 198-202.	3.0	243
103	Interferon-Î²1bin the treatment of multiple sclerosis. Expert Opinion on Pharmacotherapy, 2005, 6, 2877-2886.	1.8	14
104	Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 306-309.	3.0	184
105	IFN-Î² treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing -remitting multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 630-635.	3.0	9
106	Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 413-416.	3.0	30
107	Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology, 2004, 62, 1653-1653.	1.1	26
108	Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes. Archives of Neurology, 2004, 61, 222.	4.5	32

#	Article	IF	Citations
109	Transcription-Based Prediction of Response to IFNÎ² Using Supervised Computational Methods. PLoS Biology, 2004, 3, e2.	5.6	144
110	Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange. Journal of Neurology, 2003, 250, 243-244.	3.6	4
111	Clinically definite multiple sclerosis after radiological Schilder-like onset. Journal of Neurology, 2003, 250, 871-873.	3.6	5
112	Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes and Immunity, 2003, 4, 147-152.	4.1	77
113	Myelopathy in seronegative SjÃ¶gren syndrome and/or primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 256-259.	3.0	22
114	Unconventional therapy in multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 320-322.	3.0	18
115	Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients. European Cytokine Network, 2003, 14, 154-7.	2.0	9
116	The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-Î². Journal of Neuroimmunology, 2002, 130, 194-201.	2.3	78
117	Assessment of different treatment failure criteria in a cohort of relapsingâ€“remitting multiple sclerosis patients treated with interferon Î²: Implications for clinical trials. Annals of Neurology, 2002, 52, 400-406.	5.3	114
118	Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. American Journal of Neuroradiology, 2002, 23, 989-94.	2.4	56
119	Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. NMR in Biomedicine, 2000, 13, 57-63.	2.8	41
120	Asterixis associated with anatomic cerebral lesions: a study of 45 cases. Acta Neurologica Scandinavica, 1995, 91, 377-381.	2.1	23
121	Serum Homocysteine Levels in Multiple Sclerosis. Archives of Neurology, 1994, 51, 1181-1181.	4.5	23